Epidiolex (Cannabidiol (Cbd)) Patent Expiration, LOE Window & CMS Spending

Epidiolex (Cannabidiol (Cbd)) by Jazz Pharmaceuticals: FDA Orange Book core substance LOE 2039-04-26 (last listed 2042-09-24), 0 AB generics, $726.6M 2024 CMS Part D & Medicaid spend, and 1 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorJazz Pharmaceuticals
FDA Application & PathwayN210365 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2039-04-26
Last Listed Patent or Exclusivity Date2042-09-24
Orange Book Patents (*PED Extensions)33 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$726.6M
2024 Medicare Part D Spend$207.4M
2024 Medicaid Spend$519.2M
Reported Wholesale Price Change (CA SB 17)1 WAC filings (max 19.9% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Jazz Pharmaceuticals across sibling Meru public-data platforms.